A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
Public ClinicalTrials.gov record NCT04363801. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Study identification
- NCT ID
- NCT04363801
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 247 participants
Conditions and interventions
Interventions
- DKN-01 300mg Drug
- DKN-01 600mg Drug
- DKN-01 400mg Drug
- Tislelizumab 200mg Drug
- Tislelizumab 400mg Drug
- Oxaliplatin Drug
- Capecitabine 1000mg/ m2 twice daily (BID) Drug
- Leucovorin Calcium Drug
- Fluorouracil Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 29, 2020 (Actual)
- Primary completion
- Mar 31, 2025 (Actual)
- Completion
- Mar 31, 2025 (Actual)
- Last update posted
- Oct 9, 2025
2020 – 2025
United States locations
- U.S. sites
- 23
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Cancer Center | Phoenix | Arizona | 85054 | — |
| University of Arizona | Tucson | Arizona | 85724 | — |
| City of Hope | Duarte | California | 91010 | — |
| The Angeles Clinic Research Institute - A Cedars-Sinai Affiliate | Los Angeles | California | 90025 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| UCLA | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange | California | 92868 | — |
| University of California San Francisco | San Francisco | California | 94158 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| AdventHealth Cancer Institute | Orlando | Florida | 32804 | — |
| Northwestern University Robert H. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Pontchartrain Cancer Center | Covington | Louisiana | 70433 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04363801, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04363801 live on ClinicalTrials.gov.